Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.40−0.36 (-1.52%)
Close on Nov 18, 2026Market cap $1.12BP/E –Yield –
Rapport Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Rapport Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$121.18M. For fiscal 2025 it was -$88.09M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$88.09M | – |
| FY2024 | Dec 31, 2024 | -$67.23M | – |
| FY2023 | Dec 31, 2023 | -$28.82M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$41.63M | – |
| Q2 FY2026 | Jun 30, 2026 | -$41.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.67M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.69M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.48M | – |
See a number that looks wrong?